Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables (2021 - 2025)

Historic Receivables for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $182967.0.

  • InMed Pharmaceuticals' Receivables fell 3031.66% to $182967.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $182967.0, marking a year-over-year decrease of 3031.66%. This contributed to the annual value of $465104.0 for FY2025, which is 124035.73% up from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Receivables stood at $182967.0, which was down 3031.66% from $343469.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Receivables ranged from a high of $465104.0 in Q2 2025 and a low of $14842.0 during Q3 2021
  • Its 5-year average for Receivables is $157786.9, with a median of $84837.0 in 2022.
  • In the last 5 years, InMed Pharmaceuticals' Receivables crashed by 4803.44% in 2024 and then surged by 124035.73% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables (Quarter) stood at $50304.0 in 2021, then soared by 62.31% to $81647.0 in 2022, then fell by 18.21% to $66775.0 in 2023, then soared by 293.21% to $262569.0 in 2024, then crashed by 30.32% to $182967.0 in 2025.
  • Its Receivables was $182967.0 in Q4 2025, compared to $343469.0 in Q3 2025 and $465104.0 in Q2 2025.